KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Interest Expenses (2016 - 2026)

Gsk has reported Interest Expenses over the past 18 years, most recently at -$225.1 million for Q1 2026.

  • For Q1 2026, Interest Expenses fell 10.34% year-over-year to -$225.1 million; the TTM value through Mar 2026 reached -$1.6 billion, down 9.66%, while the annual FY2025 figure was $932.4 million, 8.59% up from the prior year.
  • Interest Expenses for Q1 2026 was -$225.1 million at Gsk, up from -$932.4 million in the prior quarter.
  • Over five years, Interest Expenses peaked at -$202.7 million in Q3 2024 and troughed at -$1.0 billion in Q4 2022.
  • A 5-year average of -$400.9 million and a median of -$235.7 million in 2022 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: plummeted 306.83% in 2022 and later rose 14.66% in 2024.
  • Year by year, Interest Expenses stood at -$1.0 billion in 2022, then increased by 4.66% to -$983.0 million in 2023, then rose by 12.65% to -$858.7 million in 2024, then dropped by 8.59% to -$932.4 million in 2025, then soared by 75.85% to -$225.1 million in 2026.
  • Business Quant data shows Interest Expenses for GSK at -$225.1 million in Q1 2026, -$932.4 million in Q4 2025, and -$225.3 million in Q3 2025.